BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 32700107)

  • 1. The biological basis and function of GNAS mutation in pseudomyxoma peritonei: a review.
    Lin YL; Ma R; Li Y
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2179-2188. PubMed ID: 32700107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.
    Pietrantonio F; Berenato R; Maggi C; Caporale M; Milione M; Perrone F; Tamborini E; Baratti D; Kusamura S; Mariani L; Niger M; Mennitto A; Gloghini A; Bossi I; Settanni G; Busico A; Bagnoli PF; Di Bartolomeo M; Deraco M; de Braud F
    J Transl Med; 2016 May; 14(1):125. PubMed ID: 27154293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward the molecular dissection of peritoneal pseudomyxoma.
    Pietrantonio F; Perrone F; Mennitto A; Gleeson EM; Milione M; Tamborini E; Busico A; Settanni G; Berenato R; Caporale M; Morano F; Bossi I; Pellegrinelli A; Di Bartolomeo M; de Braud F; Baratti D; Bowne WB; Kusamura S; Deraco M
    Ann Oncol; 2016 Nov; 27(11):2097-2103. PubMed ID: 27502722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry.
    Nummela P; Saarinen L; Thiel A; Järvinen P; Lehtonen R; Lepistö A; Järvinen H; Aaltonen LA; Hautaniemi S; Ristimäki A
    Int J Cancer; 2015 Mar; 136(5):E282-9. PubMed ID: 25274248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A GNAS mutation found in pancreatic intraductal papillary mucinous neoplasms induces drastic alterations of gene expression profiles with upregulation of mucin genes.
    Komatsu H; Tanji E; Sakata N; Aoki T; Motoi F; Naitoh T; Katayose Y; Egawa S; Unno M; Furukawa T
    PLoS One; 2014; 9(2):e87875. PubMed ID: 24498386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC2 is a molecular marker for pseudomyxoma peritonei.
    O'Connell JT; Hacker CM; Barsky SH
    Mod Pathol; 2002 Sep; 15(9):958-72. PubMed ID: 12218214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy.
    Gleeson EM; Feldman R; Mapow BL; Mackovick LT; Ward KM; Morano WF; Rubin RR; Bowne WB
    Am J Clin Oncol; 2018 Aug; 41(8):777-783. PubMed ID: 28263231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular profiles of high-grade and low-grade pseudomyxoma peritonei.
    Noguchi R; Yano H; Gohda Y; Suda R; Igari T; Ohta Y; Yamashita N; Yamaguchi K; Terakado Y; Ikenoue T; Furukawa Y
    Cancer Med; 2015 Dec; 4(12):1809-16. PubMed ID: 26475379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudomyxoma Peritonei After a Total Pancreatectomy for Intraductal Papillary Mucinous Neoplasm With Colloid Carcinoma in Lynch Syndrome.
    Hackeng WM; de Guerre LEVM; Kuypers KC; Snoek AM; Morsink FH; Offerhaus GJA; Brosens LAA
    Pancreas; 2019 Jan; 48(1):135-138. PubMed ID: 30531244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer.
    Tokunaga R; Xiu J; Johnston C; Goldberg RM; Philip PA; Seeber A; Naseem M; Lo JH; Arai H; Battaglin F; Puccini A; Berger MD; Soni S; Zhang W; Hwang JJ; Shields AF; Marshall JL; Baba H; Korn WM; Lenz HJ
    Clin Cancer Res; 2019 May; 25(10):3096-3103. PubMed ID: 30692096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide vaccine targeting mutated
    Flatmark K; Torgunrud A; Fleten KG; Davidson B; Juul HV; Mensali N; Lund-Andersen C; Inderberg EM
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34711663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular genetic analysis of appendiceal mucinous adenomas in identical twins, including one with pseudomyxoma peritonei.
    Shih IM; Yan H; Speyrer D; Shmookler BM; Sugarbaker PH; Ronnett BM
    Am J Surg Pathol; 2001 Aug; 25(8):1095-9. PubMed ID: 11474297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Mutation and Loss of Heterozygosity by Whole-Exome Sequencing Yields Insights into Pseudomyxoma Peritonei.
    Pengelly RJ; Rowaiye B; Pickard K; Moran B; Dayal S; Tapper W; Mirnezami A; Cecil T; Mohamed F; Carr N; Ennis S
    J Mol Diagn; 2018 Sep; 20(5):635-642. PubMed ID: 29936255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple components of PKA and TGF-β pathways are mutated in pseudomyxoma peritonei.
    Saarinen L; Nummela P; Thiel A; Lehtonen R; Järvinen P; Järvinen H; Aaltonen LA; Lepistö A; Hautaniemi S; Ristimäki A
    PLoS One; 2017; 12(4):e0174898. PubMed ID: 28426742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel
    Watanabe K; Nakamura T; Onodera S; Saito A; Shibahara T; Azuma T
    Tumour Biol; 2020 Sep; 42(9):1010428320962588. PubMed ID: 32996421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline-Derived Gain-of-Function Variants of Gs
    Miyado M; Fukami M; Takada S; Terao M; Nakabayashi K; Hata K; Matsubara Y; Tanaka Y; Sasaki G; Nagasaki K; Shiina M; Ogata K; Masunaga Y; Saitsu H; Ogata T
    J Am Soc Nephrol; 2019 May; 30(5):877-889. PubMed ID: 30962325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis.
    Shetty S; Thomas P; Ramanan B; Sharma P; Govindarajan V; Loggie B
    J Surg Res; 2013 Mar; 180(1):97-103. PubMed ID: 23199549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis.
    Semino-Mora C; Liu H; McAvoy T; Nieroda C; Studeman K; Sardi A; Dubois A
    Ann Surg Oncol; 2008 May; 15(5):1414-23. PubMed ID: 18299935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNF43 mutation frequently occurs with GNAS mutation and mucin hypersecretion in intraductal papillary neoplasms of the bile duct.
    Tsai JH; Liau JY; Yuan CT; Cheng ML; Yuan RH; Jeng YM
    Histopathology; 2017 Apr; 70(5):756-765. PubMed ID: 27864998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells.
    O'Connell JT; Tomlinson JS; Roberts AA; McGonigle KF; Barsky SH
    Am J Pathol; 2002 Aug; 161(2):551-64. PubMed ID: 12163380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.